These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 24640269)

  • 1. Proton pump inhibitor prescribing and costs in a large outpatient clinic.
    Hood W; McJunkin B; Warnock A; Girme A; Smith N; Robinson B
    W V Med J; 2014; 110(1):16-21. PubMed ID: 24640269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A cost-effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease.
    Gerson LB; Robbins AS; Garber A; Hornberger J; Triadafilopoulos G
    Am J Gastroenterol; 2000 Feb; 95(2):395-407. PubMed ID: 10685741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A practice-based approach for converting from proton pump inhibitors to less costly therapy.
    Lucas LM; Gerrity MS; Anderson T
    Eff Clin Pract; 2001; 4(6):263-70. PubMed ID: 11769299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Healthcare costs of GERD and acid-related conditions in pediatric patients, with comparison between histamine-2 receptor antagonists and proton pump inhibitors.
    Kothari S; Nelson SP; Wu EQ; Beaulieu N; McHale JM; Dabbous OH
    Curr Med Res Opin; 2009 Nov; 25(11):2703-9. PubMed ID: 19775195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The extent and determinants of prescribing and adherence with acid-reducing medications: a national claims database study.
    El-Serag HB; Fitzgerald S; Richardson P
    Am J Gastroenterol; 2009 Sep; 104(9):2161-7. PubMed ID: 19568229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Marked increase in proton pump inhibitors use in Australia.
    Hollingworth S; Duncan EL; Martin JH
    Pharmacoepidemiol Drug Saf; 2010 Oct; 19(10):1019-24. PubMed ID: 20623646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histamine-2 receptor antagonists at night improve gastroesophageal reflux disease symptoms for patients on proton pump inhibitor therapy.
    Rackoff A; Agrawal A; Hila A; Mainie I; Tutuian R; Castell DO
    Dis Esophagus; 2005; 18(6):370-3. PubMed ID: 16336606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proton pump inhibitors or histamine-2 receptor antagonists for the prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis.
    Harris RA; Kuppermann M; Richter JE
    Am J Gastroenterol; 1997 Dec; 92(12):2179-87. PubMed ID: 9399748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of proton pump inhibitors with lack of diagnostic indications in 22 Midwestern US skilled nursing facilities.
    Patterson Burdsall D; Flores HC; Krueger J; Garretson S; Gorbien MJ; Iacch A; Dobbs V; Homa T
    J Am Med Dir Assoc; 2013 Jun; 14(6):429-32. PubMed ID: 23583000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Maintenance therapy of mild form of GERD by H2 receptor antagonists].
    Kurosawa S
    Nihon Rinsho; 2000 Sep; 58(9):1859-64. PubMed ID: 11004816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pediatric gastroesophageal reflux disease and acid-related conditions: trends in incidence of diagnosis and acid suppression therapy.
    Nelson SP; Kothari S; Wu EQ; Beaulieu N; McHale JM; Dabbous OH
    J Med Econ; 2009; 12(4):348-55. PubMed ID: 19827992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Consumer use of over-the-counter proton pump inhibitors in patients with gastroesophageal reflux disease.
    Sheikh I; Waghray A; Waghray N; Dong C; Wolfe MM
    Am J Gastroenterol; 2014 Jun; 109(6):789-94. PubMed ID: 24896751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in proton pump inhibitor prescribing trend over the past decade and pharmacists' effect on prescribing practice at a tertiary hospital.
    Luo H; Fan Q; Xiao S; Chen K
    BMC Health Serv Res; 2018 Jul; 18(1):537. PubMed ID: 29996830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gastroesophageal reflux disease in primary care: using changes in proton pump inhibitor therapy as an indicator of partial response.
    Ruigómez A; Johansson S; Wernersson B; Fernández Cantero O; García Rodríguez LA
    Scand J Gastroenterol; 2012 Jul; 47(7):751-61. PubMed ID: 22519917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis: stress ulcer bleeding prophylaxis with proton pump inhibitors, H2 receptor antagonists.
    Barkun AN; Adam V; Martel M; Bardou M
    Value Health; 2013; 16(1):14-22. PubMed ID: 23337211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Limited ability of the proton-pump inhibitor test to identify patients with gastroesophageal reflux disease.
    Bytzer P; Jones R; Vakil N; Junghard O; Lind T; Wernersson B; Dent J
    Clin Gastroenterol Hepatol; 2012 Dec; 10(12):1360-6. PubMed ID: 22813439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disease-specific cost savings of treating nighttime versus daytime gastroesophageal reflux disease in an employed population.
    Doan QV; Lange SM; Elfant A; Aguilar D; Reyes E; Lynn RB; Dubois RW
    J Med Econ; 2008; 11(1):23-40. PubMed ID: 19450108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of proton pump inhibitor compliance on health-care resource utilization and costs in patients with gastroesophageal reflux disease.
    Gosselin A; Luo R; Lohoues H; Toy E; Lewis B; Crawley J; Duh MS
    Value Health; 2009; 12(1):34-9. PubMed ID: 19895371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and safety of proton pump inhibitors in infantile gastroesophageal reflux disease.
    Higginbotham TW
    Ann Pharmacother; 2010 Mar; 44(3):572-6. PubMed ID: 20124466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-term treatment of gastroesophageal reflux disease.
    van Pinxteren B; Numans ME; Lau J; de Wit NJ; Hungin AP; Bonis PA
    J Gen Intern Med; 2003 Sep; 18(9):755-63. PubMed ID: 12950485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.